home / stock / bitrf / bitrf news
Introduction The discovery of a safe and highly effective cure for Chronic Hepatitis C is perhaps one of the intriguing biotech success stories of the decade. Over the course of 20 years, the standard of care for Hepatitis C had evolved from a combined course of ribavarin and pegylated i...
We're back! I'm your curator, Michael Hopkins. We have some ideas from the biotech side, along with a healthcare REIT. Today, contributors like Brad Thomas , William Meyers , and BZ Equity Research are in the Editors' Picks spotlight. Here are today's Editors' Picks: Long Ideas ...
Introduction HIV therapeutics have undergone a substantial evolution since its inception over three decades ago. From the first controversial FDA-approved drug, Retrovir ((AZT)) to today's newest life-saving combination antiretroviral therapies, HIV therapy has seen incredible progress. Desp...